Hospital-Acquired Pneumonia Treatment in Immunocompromised Adults

Recommended Antibiotic Regimens

• The Infectious Diseases Society of America recommends dual antipseudomonal coverage plus MRSA coverage for hospital-acquired pneumonia in immunocompromised adults, typically with piperacillin-tazobactam 4.5g IV q6h plus an aminoglycoside, and vancomycin or linezolid for MRSA coverage 1, 2
• Combination therapy with two antipseudomonal agents from different classes is recommended for high-risk patients, including piperacillin-tazobactam 4.5g IV q6h, plus one of the following: aminoglycoside, or fluoroquinolone, and MRSA coverage with vancomycin or linezolid 1, 2
• Alternative β-lactams for piperacillin-tazobactam include cefepime 2g IV q8h, ceftazidime 2g IV q8h, imipenem 500mg IV q6h, and meropenem 1g IV q8h 1, 2

Special Considerations

• Immunocompromised patients should receive broader empiric coverage due to higher risk of multidrug-resistant organisms, combination therapy rather than monotherapy, and MRSA coverage should be included in the initial regimen 1, 2

Adjustment of Therapy

• Obtain appropriate cultures before initiating antibiotics, and adjust therapy based on culture results and clinical response 2, 3
• For confirmed methicillin-sensitive S. aureus (MSSA), narrow to oxacillin, nafcillin, or cefazolin 2

Common Pitfalls to Avoid

• Using monotherapy in high-risk patients when combination therapy is indicated, and failure to consider local antimicrobial resistance patterns when selecting empiric therapy 2
• Overuse of broad-spectrum antibiotics in low-risk patients contributes to antimicrobial resistance 2